Clinical cancer advances 2018: Annual report on progress against cancer from the American Society of Clinical Oncology

Journal of Clinical Oncology

Volumn 36, Issue 10, 2018, Pages 1020-1044

  Heymach, John ^b   Krilov, Lada ^a   Alberg, Anthony ^d   Baxter, Nancy ^e   Chang, Susan Marina ^f   Corcoran, Ryan ^h   Dale, William ^g   DeMichele, Angela ^j   Magid Diefenbach, Catherine S ^k   Dreicer, Robert ^c   Epstein, Andrew S ^l   Gillison, Maura L ^b   Graham, David L ⁿ   Jones, Joshua ^j   Ko, Andrew H ^f   Lopez, Ana Maria ^o   Maki, Robert G ^m   Rodriguez Galindo, Carlos ^p   Schilsky, Richard L ^a   Sznol, Mario ^q   Westin, Shannon Neville ^b,g   Burstein, Harold ⁱ   more..

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k UNIVERSITY OF NEW YORK   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

ⁿ CAROLINAS MEDICAL CENTER   (United States)

^o UNIVERSITY OF UTAH   (United States)

^p ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^q YALE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ANTINEOPLASTIC MONOCLONAL ANTIBODY; BEVACIZUMAB; IMMUNE CHECKPOINT INHIBITOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; ADVERSE EVENT; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER GENE THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESEARCH; CANCER RISK; CAR T CELL THERAPY; CELL THERAPY; CHILDHOOD LEUKEMIA; CLINICAL DECISION MAKING; COPING BEHAVIOR; ELECTRONIC CIGARETTE; HEALTH DISPARITY; HIGH RISK PATIENT; HUMAN; INTERPERSONAL COMMUNICATION; LUNG CANCER; MAINTENANCE THERAPY; MALIGNANT NEOPLASM; MEDICAID; MEDICAL SOCIETY; MELANOMA; MULTIPLE MYELOMA; ONCOLOGY; OVARY CANCER; PATIENT CARE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RISK FACTOR; SEXUAL AND GENDER MINORITY; SMOKING; TERMINAL CARE; THERAPY EFFECT; CHILD; NEOPLASM; PEDIATRICS; PROCEDURES;

CHILD; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PEDIATRICS;

EID: 85045017824     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.77.0446     Document Type: Article

References (108)

1. American Cancer Society: Cancer facts and figures 2017. https://www.cancer.org/research/cancerfacts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html
2. American Cancer Society: Cancer treatment & survivorship facts & figures 2016-2017. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/cancer-treatment-and-survivorship-facts-and-figures-2016-2017.pdf
3. Bluethmann SM, Mariotto AB, Rowland JH: Anticipating the “Silver Tsunami”: Prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev 25:1029-1036, 2016
4. National Cancer Institute: SEER cancer statistics review (CSR), 1975-2014. https://seer.cancer.gov/csr/1975_2014/
5. United for Medical Research: New data shows economic impact of NIH research in 50 states + DC. http://www.unitedformedicalresearch.com/new-data-shows-economic-impact-of-nih-research-in-50-states-dc/
6. Mahan D, Makomva K: In your own backyard: How NIH funding helps your state's economy. http://www.policyarchive.org/handle/10207/8274
7. National Institutes of Health: Impact of NIH research: Our society. https://www.nih.gov/aboutnih/what-we-do/impact-nih-research/our-society
8. National Cancer Institute: NCI budget and appropriations. https://www.cancer.gov/about-nci/budget
9. National Institutes of Health: NIH data book. https://report.nih.gov/nihdatabook/
10. Jeha S, Gaynon PS, Razzouk BI, et al: Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 24:1917-1923, 2006
11. von Stackelberg A, Locatelli F, Zugmaier G, et al: Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol 34:4381-4389, 2016
12. Grupp SA, Laetsch TW, Buechner J, et al: Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia. Blood 128:221, 2016
13. Buechner J, Grupp SA, Maude SL, et al: Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/ refractory (r/r) acute lymphoblastic leukemia (all): Update to the interim analysis. 22nd Congress of the European Hematology Association, Madrid, Spain, June 22-25, 2017
14. US Food and Drug Administration: FDA approval brings first gene therapy to the United States. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm
15. Schuster SJ, Bishop MR, Tam C, et al: Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLCBL)-An interim analysis. 22nd Congress of the European Hematology Association Madrid, Madrid, Spain, June 22-25, 2017
16. Locke FL, Neelapu SS, Bartlett NL, et al: Clinical and biologic covariates of outcomes in zuma-1: A pivotal trial of axicabtagene ciloleucel (AXI-CEL; KTE-C19) in patients with refractory aggressive non-hodgkin lymphoma (NHL). 22nd World Congress of the European Hematology Association Madrid, Madrid, Spain, June 22-25, 2017
17. US Food and Drug Administration: FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581216.htm
18. Fan F, Zhao W, Liu J, et al: Durable remissions with BCMA-specific chimeric antigen receptor (CAR)modified T cells in patients with refractory/relapsed multiple myeloma. J Clin Oncol 35, 2017 (suppl; abstr LBA3001)
19. Song M, Giovannucci E: Preventable incidence and mortality of carcinoma associated with lifestyle factors among white adults in the United States. JAMA Oncol 2:1154-1161, 2016
20. Gillison ML, Broutian T, Graubard B, et al: Impact of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the U.S. J Clin Oncol 35:6003, 2017 (suppl)
21. Soneji S, Barrington-Trimis JL, Wills TA, et al: Association between initial use of e-cigarettes and subsequent cigarette smoking among adolescents and young adults: A systematic review and meta-analysis. JAMA Pediatr 171:788-797, 2017
22. Kasza KA, Ambrose BK, Conway KP, et al: Tobacco-product use by adults and youths in the United States in 2013 and 2014. N Engl J Med 376: 342-353, 2017
23. Ghiasvand R, Rueegg CS, Weiderpass E, et al: Indoor tanning and melanoma risk: Long-term evidence from a prospective population-based cohort study. Am J Epidemiol 185:147-156, 2017
24. LoConte NK, Brewster AM, Kaur JS, et al: Alcohol and cancer: A statement of the American Society of Clinical Oncology. J Clin Oncol [epub ahead of print on November 7, 2017]
25. GBD 2016 Causes of Death Collaborators: Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1151-1210, 2017
26. US Food and Drug Administration: FDA grants accelerated approval to pembrolizumab for first tissue/ site agnostic indication. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm
27. Le DT, Durham JN, Smith KN, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409-413, 2017
28. Hyman DM, Laetsch TW, Kummar S, et al: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J Clin Oncol 35, 2017 (suppl; abstr LBA2501)
29. Laetsch TW, DuBois SG, Nagasubramanian R, et al: A pediatric phase I study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. J Clin Oncol 35:10510, 2017 (suppl)
30. National Cancer Institute: Cancer stat facts: Lung and bronchus cancer. https://seer.cancer.gov/statfacts/html/lungb.html
31. Hanna N, Johnson D, Temin S, et al: Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3484-3515, 2017
32. Hida T, Nokihara H, Kondo M, et al: Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): An open-label, randomised phase 3 trial. Lancet 390:29-39, 2017
33. Peters S, Camidge DR, Shaw AT, et al: Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:829-838, 2017
34. US Food and Drug Administration: Pembrolizumab (Keytruda) 5-10-2017. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm558048.htm
35. Antonia SJ, Villegas A, Daniel D, et al: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919-1929, 2017
36. Nanda R, Liu MC, Yau C, et al: Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. J Clin Oncol 35:506, 2017
37. Gillison ML, Blumenschein GR, Fayette J, et al: Nivolumab (Nivo) vs investigator's choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy. J Clin Oncol 35:6019, 2017
38. Harrington KJ, Ferris RL, Blumenschein G Jr, et al: Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): Health-related quality-of-life results from a randomised, phase 3 trial. Lancet 18: 1104-1115, 2017
39. Escudier B, Tannir N, McDermott D, et al: CheckMate 214: Efficacy and safety of nivolumab 1 ipilimumab (N1I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Presented at the European Society for Medical Oncology 2017 Congress, Madrid, Spain, September 8-12, 2017
40. El-Khoueiry AB, Sangro B, Yau T, et al: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet Oncol 389:2492-2502, 2017
41. Hellmann MD, Ott PA, Zugazagoitia J, et al: Nivolumab (nivo) 6 ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. J Clin Oncol 35:8503, 2017
42. Antonia SJ, Villegas A, Daniel D, et al: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919-1929, 2017
43. Weber J, Mandala M, Del Vecchio M, et al: Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377: 1824-1835, 2017
44. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al: Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345-1356, 2017
45. Kaufman HL, Russell J, Hamid O, et al: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17:1374-1385, 2016
46. Papadopoulos KP, Owonikoko TK, Johnson ML, et al: REGN2810: A fully human anti-PD-1 monoclonal antibody, for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)-Initial safety and efficacy from expansion cohorts (ECs) of phase I study. J Clin Oncol 35:9503, 2017
47. Kang Y-K, Satoh T, Ryu M-H, et al: Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial. J Clin Oncol 35, 2017 (suppl; abstr 2)
48. Fuchs CS, Doi T, Jang RW-J, et al: KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J Clin Oncol 35: 4003, 2017
49. US Food and Drug Administration: FDA approves new, targeted treatment for bladder cancer. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm501762.htm
50. US Food and Drug Administration: Nivolumab for treatment of urothelial carcinoma. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm539646.htm
51. US Food and Drug Administration: Durvalumab (Imfinzi). https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555930.htm
52. US Food and Drug Administration: FDA grants accelerated approval to avelumab for urothelial carcinoma. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm557162.htm
53. USFoodandDrugAdministration:Pembrolizumab (Keytruda): Advanced or metastatic urothelial carcinoma. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm559300.htm
54. Bellmunt J, de Wit R, Vaughn DJ, et al: Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015-1026, 2017
55. O'Donnell PH, Grivas P, Balar AV, et al: Bio-marker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). J Clin Oncol 35:4502, 2017 (suppl 15)
56. Balar AV, Galsky MD, Rosenberg JE, et al: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. Lancet 389:67-76, 2017
57. Institute of Medicine: Institute of Medicine Forum on Drug Discovery, Development, and Translation: Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. Washington, DC, National Academies Press, 2010
58. Stupp R, Taillibert S, Kanner AA, et al: Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: A randomized clinical trial. JAMA 314: 2535-2543, 2015
59. Stupp R, Hegi ME, Idbaih A, et al: Tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): Final results of a randomized, multi-center, phase III trial. Cancer Res 77, 2017 (abstr CT007)
60. Perry JR, Laperriere N, O'Callaghan CJ, et al: Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376: 1027-1037, 2017
61. van den Bent M, Baumert B, Erridge SC, et al: Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non co-deleted anaplastic glioma: A phase 3, randomized, open-label intergroup study. Lancet 390:1645-1653, 2017
62. Robson M, Im SA, Senkus E, et al: Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523-533, 2017
63. von Minckwitz G, Procter M, de Azambuja E, et al: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377: 122-131, 2017
64. Goss PE, Ingle JN, Pritchard KI, et al: Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375:209-219, 2016
65. Mamounas EP, Bandos H, Lembersky BC, et al: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42, San Antonio Breast Cancer Symposium, San Antonio, Texas, December 7, 2016
66. Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, et al: Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): A randomised, phase 3 trial. Lancet Oncol 18:1502-1511, 2017
67. Coleman RL, Brady MF, Herzog TJ, et al: Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/ Gynecologic Oncology Group study GOG-0213): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18:779-791, 2017
68. US Food and Drug Administration: FDA approves olaparib tablets for maintenance treatment in ovarian cancer. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm572143.htm
69. Pujade-Lauraine E, Ledermann JA, Selle F, et al: Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18:1274-1284, 2017
70. Coleman RL, Oza AM, Lorusso D, et al: Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:1949-1961, 2017
71. Long GV, Hauschild A, Santinami M, et al: Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377:1813-1823, 2017
72. Shipley WU, Seiferheld W, Lukka HR, et al: Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376: 417-428, 2017
73. Fizazi K, Tran N, Fein L, et al: Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352-360, 2017
74. James ND, de Bono JS, Spears MR, et al: Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377: 338-351, 2017
75. Hamdy FC, Donovan JL, Lane JA, et al: 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375:1415-1424, 2016
76. Donovan JL, Hamdy FC, Lane JA, et al: Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 375:1425-1437, 2016
77. Wilt TJ, Jones KM, Barry MJ, et al: Follow-up of prostatectomy versus observation for early prostate cancer. N Engl J Med 377:132-142, 2017
78. Barocas DA, Alvarez J, Resnick MJ, et al: Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA 317: 1126-1140, 2017
79. Chen RC, Basak R, Meyer AM, et al: Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA 317:1141-1150, 2017
80. Shi Q, Sobrero AF, Shields AF, et al: Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. J Clin Oncol 35, 2017 (suppl; sbstr LBA1)
81. Faries MB, Thompson JF, Cochran AJ, et al: Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 376: 2211-2222, 2017
82. Moran MS, Schnitt SJ, Giuliano AE, et al: Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Ann Surg Oncol 21:704-716, 2014
83. Morrow M, Abrahamse P, Hofer TP, et al: Trends in reoperation after initial lumpectomy for breast cancer: Addressing overtreatment in surgical management. JAMA Oncol 3:1352-1357, 2017
84. Erlandsson J, Holm T, Pettersson D, et al: Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): A multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 18:336-346, 2017
85. Marur S, Li S, Cmelak AJ, et al: E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx-ECOG-ACRIN Cancer Research Group. J Clin Oncol 35:490-497, 2017
86. Chen AM, Felix C, Wang PC, et al: Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: A single-arm, phase 2 study. Lancet Oncol 18:803-811, 2017
87. Rodenbach RA, Brandes K, Fiscella K, et al: Promoting end-of-life discussions in advanced cancer: Effects of patient coaching and question prompt lists. J Clin Oncol 35:842-851, 2017
88. Sudore RL, Boscardin J, Feuz MA, et al: Effect of the PREPARE Website vs an easy-to-read advance directive on advance care planning documentation and engagement among veterans: A randomized clinical trial. JAMA Intern Med 177:1102-1109, 2017
89. Nipp RD, Greer JA, El-Jawahri A, et al: Coping and prognostic awareness in patients with advanced cancer. J Clin Oncol 35:2551-2557, 2017
90. Gilligan T, Coyle N, Frankel RM, et al: Patient-clinician communication: American Society of Clinical Oncology consensus guideline. J Clin Oncol 35: 3618-3632, 2017
91. Wang K, Eblan MJ, Deal AM, et al: Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: Pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol 35:1387-1394, 2017
92. Dess RT, Sun Y, Matuszak MM, et al: Cardiac events after radiation therapy: Combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. J Clin Oncol 35: 1395-1402, 2017
93. Armenian SH, Lacchetti C, Barac A, et al: Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 35:893-911, 2017
94. Hoskin P, Misra V, Hopkins K, et al: SCORAD III: Randomized noninferiority phase III trial of single-dose radiotherapy (RT) compared to multifraction RT in patients (pts) with metastatic spinal canal compression (SCC). J Clin Oncol 35, 2017 (suppl; abstr LBA10004)
95. Mustian KM, Alfano CM, Heckler C, et al: Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: A meta-analysis. JAMA Oncol 3:961-968, 2017
96. Bower JE, Bak K, Berger A, et al: Screening, assessment, and management of fatigue in adult survivors of cancer: An American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol 32:1840-1850, 2014
97. Basch E, Deal AM, Dueck AC, et al: Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318:197-198, 2017
98. Hess V, Grossert A, Alder J, et al: Web-based stress management for newly diagnosed cancer patients (STREAM): A randomized, wait-list controlled intervention study. J Clin Oncol 35, 2017 (suppl; abstr LBA10002)
99. Candido Dos Reis FJ, Lynn S, Ali HR, et al: Crowdsourcing the general public for large scale molecular pathology studies in cancer. EBioMedicine 2:681-689, 2015
100. Meric-Bernstam F SM, Infante JR, et al: Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. J Clin Oncol 35:2505, 2017 (suppl)
101. Yurgelun MB, Chenevix-Trench G, Lippman SM: Translating germline cancer risk into precision prevention. Cell 168:566-570, 2017
102. Spira A, Disis ML, Schiller JT, et al: Leveraging premalignant biology for immune-based cancer prevention. Proc Natl Acad Sci USA 113:10750-10758, 2016
103. Fitzmaurice C, Allen C, Barber RM, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the Global Burden of Disease Study. JAMA Oncol 3: 524-548, 2017
104. McGuire S: World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 7:418-419, 2016
105. Singh GK, Jemal A: Socioeconomic and racial/ ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950-2014: Over six decades of changing patterns and widening inequalities. J Environ Public Health 2017:2819372, 2017
106. Abdelsattar ZM, Hendren S, Wong SL: The impact of health insurance on cancer care in disadvantaged communities. Cancer 123:1219-1227, 2017
107. Pan HY, Walker GV, Grant SR, et al: Insurance status and racial disparities in cancer-specific mortality in the United States: A population-based analysis. Cancer Epidemiol Biomarkers Prev 26:869-875, 2017
108. Polite BN, Adams-Campbell LL, Brawley OW, et al: Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute. J Clin Oncol 35:3075-3082, 2017